Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.34

€0.34

-4.550%
-0.016
-4.550%
€12.54
 
16:09 / Tradegate WKN: A3DQSD / Symbol: CLRB / Name: Cellectar BioSciences / Stock / Pharmaceuticals / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15JS chart by amCharts
Select a timeframe to show chart data
From: to:
Zoom:
Loading data...

Cellectar BioSciences Inc. Stock

Heavy losses for Cellectar BioSciences Inc. today as the stock fell by -€0.016 (-4.550%).
Currently there is a rather negative sentiment for Cellectar BioSciences Inc. with 4 Buy predictions and 8 Sell predictions..
However, we have a potential of 3471.43% for Cellectar BioSciences Inc. as the target price of 12 € is above the current price of 0.34 €.
Criterium "Management" is seen as the biggest plus for Cellectar BioSciences Inc. stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Cellectar BioSciences Inc. in the next few years

Pros
?
B****
?
S********** s********
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Cellectar BioSciences Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Cellectar BioSciences Inc. -4.550% 54.386% 49.153% -87.692% 12.821% -91.189% -
Beximco Pharmaceuticals Ltd. GDR 2.420% -1.429% 3.500% -1.429% 0.000% -55.484% -8.407%
SELLAS Life Sciences Group Inc 0.140% -5.305% -6.176% 9.846% 51.753% -47.673% -52.918%
Eledon Pharmaceuticals Inc. -5.150% -1.449% -4.225% 8.800% -33.333% -8.108% -67.433%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

Analyzing the financials of Cellectar BioSciences, a player in the pharmaceutical sector, reveals a company that is currently operating in a challenging financial position. With a market capitalization of approximately $71.42 million, the figures present a mixed bag of opportunities and risks. A look into their income statement, balance sheet, and cash flow statement indicates a firm that is still in its developmental phase, struggling with profitability in a highly competitive field.

Market Capitalization: At about $71.42 million, Cellectar’s market cap places it in a relatively manageable territory for potential growth. Smaller market caps can lead to rapid appreciation in share value if positive news is forthcoming, especially in a volatile sector like pharmaceuticals.

Book Value: The book value per share of $0.274 indicates that, despite current operational challenges, the company's tangible assets may provide a cushion for investors. This value is critical in assessing the minimum the company is worth, which can be appealing for long-term investors.

Comments

Cellectar Biosciences, Inc. (NASDAQ: CLRB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CLRB provided by MarketBeat
Show more

Cellectar Biosciences, Inc. (NASDAQ: CLRB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CLRB provided by MarketBeat
Show more

Cellectar Biosciences, Inc. (NASDAQ: CLRB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CLRB provided by MarketBeat
Show more